Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mark Burdt (NPI 1245349182)

Field	Value
Entity Type	Individual
Organization	Mark Burdt
Address	8421 Plum Dr
City	Urbandale
State	IA
ZIP	50322
Taxonomy	Rheumatology Physician
NPI Enumerated	August 30, 2006

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single‑payer: lifetime Medicare revenue is $1.1M while there is no Medicaid billing on file. That concentration means the practice’s financial exposure and growth opportunities are tied to Medicare-covered services and beneficiary volume rather than to a mixed Medicaid/Medicare payer mix.

Revenue is highly concentrated in a small set of biologic drug administrations: the precomputed top 3 Medicare codes account for 66.8% of the provider’s total Medicare revenue, with J0129 alone contributing $421.6K (38.1%). This level of concentration indicates the practice depends disproportionately on a few high‑revenue injectable biologics for its Medicare income.

The code mix points to a rheumatology practice that operates an in‑office biologics/infusion service line: the highest‑revenue codes are J0129, J0897, and J1745 (abatacept, denosumab, infliximab), and the record also includes other injectable biologics such as J0717 and J3111. Combined with frequent administration codes and related drug codes, this pattern is consistent with a practice that both prescribes and directly administers parenteral biologic therapies rather than handing injections off to outside infusion centers.

The provider appears to maintain infusion and chemotherapy administration capacity: Medicare administration and infusion codes 96413 (84th percentile), 96401 (83th percentile), 96415 (82th percentile), and 96365 are present in the top services, which supports the observation that this site regularly delivers multi‑drug infusions or extended infusions in the office setting. Those percentiles place the practice above many peers for infusion activity while still within the dataset’s characterization of "typical, unremarkable volume."

Competitive standing for the top drug codes is mixed: J0897 ranks relatively high at #949 of 10057 providers (90th percentile) suggesting stronger than average denosumab administration versus national peers, while J0129 (#348 of 1221, 71th percentile) and J1745 (#426 of 1352, 68th percentile) sit in middle terciles and are labeled "typical, unremarkable volume." Overall, the practice is not a nationwide dominant player for these biologics but does show pockets of comparative strength on specific drugs.

Ambulatory evaluation‑and‑management volume is comparatively strong: 99214 and 99213 both rank in the 95th percentile (99214 at #24132 of 479517 and 99213 at #20823 of 457151) and are labeled "notably above typical national volume," indicating higher office visit throughput per Medicare peers and a steady outpatient panel that complements the infusion/business lines.

The practice offers onsite diagnostic and monitoring support, with high relative volumes for routine labs and imaging used in rheumatology/osteoporosis care: venous puncture 36415 (93th percentile), CBC 85027 (93th percentile), creatinine 82565 (94th percentile), and DXA 77080 (86th percentile) all appear in the top codes. This clustering of lab and DXA services supports a care model that monitors therapy safety and bone health in the practice rather than outsourcing those services.

The provider has long tenure in the Medicare program, with the NPI enumerated on 2006-08-30 (~20 years ago), which indicates an established practice history. Coupled with lifetime Medicare revenue of $1.1M and the service mix described above, the data portray a stable, Medicare‑focused rheumatology operation with specialized in‑office administration of biologics and associated diagnostic services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

58 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	12,400	$30	$421.6K
J0897	Injection, denosumab, 1 mg	11,160	$20	$200.9K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4,460	$30	$116K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	23,200	$1	$92.8K
J3111	Injection, romosozumab-aqqg, 1 mg	8,820	$10	$70.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	730	$80	$59.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	390	$100	$36.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	580	$60	$34.7K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	270	$50	$14.3K
99490	The clinical staff provides services directed by the provider to support and coordinate a patient’s care across multiple disciplines. The patient has two or more chronic conditions that place the…	210	$50	$9.7K

Showing 1–10 of 58

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 58 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Mark Burdt — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

58 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	20	5,950	$30	$218.3K
J3111	14	20	12,180	$10	$112K
J0717	9	20	23,500	$1	$93.9K
J1745	6	20	3,460	$30	$92.3K
J0897	15	190	1,920	$20	$74.1K
96413	18	80	210	$90	$24K
99214	222	4,690	100	$70	$14.4K
99490	86	330	130	$40	$9K
99213	155	4,740	100	$50	$8K
96401	7	40	90	$50	$7.4K

Showing 1–10 of 58

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mark Burdt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0
Clarke County Public Hospital	IA	Critical Access Hospital	$0	$5.1M
Matthew Mcknight	IA	Foot & Ankle Surgery Podiatrist	$4.7M	$23.5K
Clarke County Public Hospital	IA	Rural Health Clinic/Center	$0	$4.5M

Nearby Providers

Other providers in the same ZIP code as Mark Burdt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mosaic	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$177.4M
The Respite Connection, Inc.	IA	Community/Behavioral Health Agency	$0	$38.1M
Unitypoint At Home	IA	Durable Medical Equipment & Medical Supplies	$0	$16.5M
Unitypoint At Home	IA	Home Infusion Therapy Pharmacy	$0	$15.4M
New Beginnings Counseling Service, LLC	IA	Community/Behavioral Health Agency	$0	$6.3M
A-1 Iowa Dental PLLC	IA	Dentist	$0	$5.4M
Urbandale Community School District	IA	Local Education Agency (LEA)	$0	$4.4M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$3.9M
Acs Medical LLC	IA	Durable Medical Equipment & Medical Supplies	$0	$3.6M
Wellserve Health, Inc.	IA	Community/Behavioral Health Agency	$0	$2.8M

Mark Burdt — Billing Profile & Reimbursement Data

Sign up for Mark Burdt — Billing Profile & Reimbursement Data policy alerts

Mark Burdt — Billing Profile & Reimbursement Data

Sign up for Mark Burdt — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References